Guanfacine vs Clonidine: Sedation, Duration, and Typical Uses

If you’ve been offered guanfacine or clonidine for ADHD, you may have heard they’re basically the same drug. They do share a class and a mechanism, but the differences show up in the parts of your day you notice most: how sleepy you feel, how long a dose lasts, and what happens if you miss a few.

Both medicines work on alpha-2 receptors, which act like built-in brakes on norepinephrine signaling. Engaging those brakes in the brainstem lowers blood pressure and heart rate, which is why both began as blood pressure pills. In the prefrontal cortex, the region that helps with attention and impulse control, the same receptor family seems to steady focus. The difference between the two is precision, and the Intuniv prescribing information says guanfacine binds the alpha-2A subtype with 15 to 20 times more affinity than the 2B or 2C subtypes.

Clonidine is the older option, and it has earned its place. A 2007 CNS Drug Reviews paper traces clonidine’s ADHD research back to the 1980s and describes guanfacine as the more selective of the two. Extended-release clonidine (Kapvay) is FDA-approved for ADHD, and in its fixed-dose trial in children and teens, both 0.2 mg and 0.4 mg a day lowered ADHD symptom scores more than placebo at 5 weeks. The results are real, and the evidence is well established.

But the research now separates these two medicines on sedation, dosing rhythm, and withdrawal, and at Siggy we believe a choice this personal deserves that level of detail. Guanfacine extended-release (Intuniv) is the more selective of the pair, taken once a day, and in older head-to-head studies it caused less sedation and a slower, milder blood pressure rebound than clonidine. This guide compares them on the things that matter day to day. What separates them has little to do with marketing and a great deal to do with receptor biology.

What This Page Covers

• How Guanfacine and Clonidine Differ
• Guanfacine vs Clonidine at a Glance
• Which One Is More Sedating?
• How Long Does Each Dose Last?
• Stopping Safely and Rebound Blood Pressure
• Typical Use Cases for Each
• What About Adults With ADHD?

How Guanfacine and Clonidine Differ

Both are central alpha-2 agonists. Neither is a stimulant, and both labels state that the drug is not a controlled substance and has no known potential for abuse or dependence. Both labels are also honest that the exact way each medicine helps ADHD isn’t known.

The main biological difference is selectivity. Guanfacine leans heavily toward the alpha-2A receptor, while clonidine acts more broadly across alpha-2 subtypes. The 2007 review notes that guanfacine also has a longer half-life and cites animal and human studies suggesting it is less sedating, with milder blood pressure effects.

One human study was small but direct. In a 1993 volunteer study, researchers gave intravenous clonidine or guanfacine to six healthy men. Sedation was significantly more pronounced after clonidine, and clonidine lowered both systolic and diastolic blood pressure, while guanfacine lowered only systolic pressure. With six people and IV doses, it points in a direction rather than settling the question.

Guanfacine vs Clonidine at a Glance

The table below pulls the practical differences from the Intuniv label and the Kapvay prescribing information for the extended-release ADHD versions.

Feature	Guanfacine ER (Intuniv)	Clonidine ER (Kapvay)
Receptor profile	Selective for alpha-2A	Broader alpha-2 activity
Doses per day	Once, morning or evening	Twice, larger or equal dose at bedtime
Starting dose	1 mg daily	0.1 mg at bedtime
Label dose range	1 to 7 mg, weight based	0.1 to 0.4 mg
Half-life	About 18 hours	About 12 to 16 hours
Somnolence, solo trials	38% vs 11% placebo	31% to 38% vs 4% placebo
Taper when stopping	1 mg every 3 to 7 days	0.1 mg every 3 to 7 days

Neither version can be swapped milligram for milligram with its immediate-release cousin, and both tablets must be swallowed whole.

Which One Is More Sedating?

Drowsiness is common with both. In the Intuniv fixed-dose trials, somnolence rose with dose, from 28% at 1 mg to 51% at 4 mg, compared with 11% on placebo. In the Kapvay monotherapy trial, somnolence affected 38% of young people on 0.2 mg a day and 31% on 0.4 mg, compared with 4% on placebo.

Those numbers look similar, but both labels warn that side effect rates from one drug’s trials can’t be directly compared with another’s. The trials used different designs, doses, and definitions. That’s why the small head-to-head data still matter, and they lean toward clonidine being the more sedating option.

The class-wide picture comes from a 2014 alpha-2 agonist meta-analysis covering 12 studies and 2,276 young people. Used alone, alpha-2 agonists produced one extra case of somnolence for about every 4 people treated, compared with placebo. Sedation led to dropouts too: in the Kapvay trial, 20% of young people on 0.4 mg stopped because of side effects, mostly somnolence and fatigue, and in the Intuniv trials, 18% stopped at 4 mg.

Moving a guanfacine dose to the evening is an option, since the Intuniv label allows morning or evening dosing. In one flexible-dose trial, though, somnolence was similar either way, at 57% with morning doses and 54% with evening doses. Our guide to guanfacine side effects walks through how sedation tends to change over the first weeks.

How Long Does Each Dose Last?

Duration is where the two part ways most clearly. The Intuniv label lists an adult half-life of about 18 hours for the extended-release tablet, which supports a single daily dose. Peak levels arrive about 5 to 6 hours after a dose.

Clonidine clears faster. Immediate-release clonidine peaks in about 3 to 5 hours, with a half-life of 12 to 16 hours. Kapvay’s extended-release design cuts the peak roughly in half and delays it by about 5 hours, but the half-life stays similar, so it’s still taken twice a day.

That rhythm shapes daily life. A once-daily guanfacine dose is simpler to remember, while clonidine’s split schedule puts the larger or equal dose at bedtime, so some of its drowsiness is timed for night. Our guide to clonidine for ADHD covers what the evidence shows about sleep.

Missed doses are handled differently too. For Kapvay, the label says to skip a missed dose and never exceed the total daily amount. For Intuniv, the label suggests your prescriber consider re-titrating after two or more missed doses in a row.

Stopping Safely and Rebound Blood Pressure

Because both medicines lower blood pressure, stopping suddenly can make it bounce back above your baseline. Both labels call for a taper. The Intuniv label reports postmarketing cases of persistent rebound hypertension after abrupt stops, including hypertensive encephalopathy, and it notes that children with stomach bugs who can’t keep medicine down may be especially at risk.

The clearest head-to-head evidence comes from a 24-week hypertension trial in 42 adults, which was randomized and double-blind. After both drugs were stopped abruptly, blood pressure and heart rate rose in both groups, but the rise after clonidine was larger and came earlier, around day 2 versus day 4 for guanfacine. Diastolic pressure climbed by 10 mm Hg or more in 64% of the clonidine group and 40% of the guanfacine group. These were adults treated for high blood pressure, so the numbers won’t map exactly onto ADHD dosing, but the pattern fits guanfacine’s longer half-life.

Guanfacine’s slower rebound doesn’t make it safe to stop on your own. If you run out, get sick and can’t take doses, or want to stop, contact your prescriber. If you develop a severe headache, chest pain, or confusion after missed doses, call 911 or get emergency care. Our guide to clonidine side effects explains what a safe taper looks like.

Typical Use Cases for Each

Both extended-release versions are FDA-approved for ADHD, either alone or added to a stimulant, and their approval trials enrolled ages 6 to 17. The meta-analysis found alpha-2 agonists helped hyperactivity, impulsivity, and inattention when used alone, and they still helped when added to a stimulant, though the added benefit was smaller.

The label differences point to a few common patterns:

• Guanfacine may suit someone who needs daytime alertness or a once-daily routine, since it sedated less in head-to-head studies and is taken once a day.
• Clonidine may suit someone whose evenings are the hardest stretch, since its schedule puts the larger or equal dose at bedtime.
• Either may suit someone who has tics along with ADHD.

That last point has guideline support. The American Academy of Neurology guideline on tics found clonidine probably reduces tic severity and guanfacine possibly does, and in children with both tics and ADHD, both improved tics and ADHD symptoms. It recommends counseling about sedation and monitoring heart rate and blood pressure with either medicine.

What About Adults With ADHD?

In the U.S., both labels establish safety and effectiveness only in ages 6 to 17, so adult use is off-label. That means the adult evidence is thinner and the dose takes more careful adjustment, not that these medicines fail in adults.

A 2023 adult nonstimulant meta-analysis found two placebo-controlled guanfacine trials, and guanfacine was more effective than placebo in them. The same analysis couldn’t pool guanfacine’s tolerability data, because only one trial reported it.

For adults, blood pressure deserves extra attention. If you take a blood pressure medicine, a heart rhythm medicine, or anything sedating, both labels warn that the effects can add up. Our guide to guanfacine for ADHD covers adult dosing questions in more depth.

With alpha-2 agonists, the tradeoffs play out over weeks. Drowsiness may fade or persist, the Intuniv label notes that blood pressure drops are largest in the first month, and a missed refill can turn into a rebound.

Keeping short notes on when you feel sleepy, how focus holds up through the day, and any dizziness gives whoever prescribes your medication a clear pattern to work from, instead of a guess at your next visit.

Guanfacine and clonidine share a class, but they don’t share a daily experience: guanfacine is more selective, lasts longer, and tends to sedate less, while clonidine’s bedtime-weighted schedule can suit evenings that won’t settle. The right choice depends on your symptoms, your schedule, your blood pressure, and what you’ve tried before.

Ready to take control of your mental health? Start your anonymous intake with Siggy and get your plan reviewed by a licensed prescriber.

This article is for education only and isn’t a substitute for personal medical advice. Talk with your own clinician before starting, changing, or stopping any medication.